Supporting high-growth life science companies

Our approach to growth equity investments

We are an engaged investor in, and a partner to, life science companies at the leading edge of innovation.

We invest in companies harnessing the transformative power of biology and technology. In particular, we focus on investments in clinical diagnostics, industrial biotechnology, biologics supply chain, and healthcare technology.

We leverage our deep scientific knowledge, operational expertise and global network for the benefit of our portfolio companies.

We have evergreen capabilities that allow us to have a longer-term horizon, and be a true partner dedicated to enabling our portfolio companies to fulfil their full potential.

What we do

We make sizeable investments in highly innovative, scalable life science companies that have recently reached, or are close to, the commercial stage, with strong long-term potential.

The combination of our long-term capital and sector expertise position us as an investor of choice for growth companies in the life science sector.

What we do

We make sizeable investments in highly innovative, scalable life science companies that have recently reached, or are close to, the commercial stage, with strong long-term potential.

The combination of our long-term capital and sector expertise position us as an investor of choice for growth companies in the life science sector.

As at 31 December 2020

  • 2019

    First direct investment

  • 700 M

    Value of investments

  • 10

    Companies in portfolio

All teams

Meet our team

We are a dedicated growth equity team with strong industry and scientific knowledge and experience based in San Francisco.

Novo Growth*
501 2nd Street, Suite 300
San Francisco, CA 94107
USA
+1 (415) 552-6686

*) Novo Growth is a team of business professionals employed by Novo Holdings Equity US Inc., which is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.